Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| CJC-1295 (with DAC) | LL-37 (Cathelicidin) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 2 mg administered once weekly via subcutaneous injection. | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. |
| Timing | Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release. | Morning administration preferred for immune support. Topical application directly to wound sites. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks between cycles. | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.
Research indicates 2 mg administered once weekly via subcutaneous injection.
Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.
12-24 week cycles with 4-8 week breaks between cycles.
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →